Here are the 10-Q quarterly reports from Aptose Biosciences Inc (APTOF) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow APTOF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APTOF filings page.
Aptose Biosciences Inc. reported another quarter of operating losses and remains under significant financial strain. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $7.6 million, widening from $5.5 million a year earlier, or $2.99 per share.
At March 31, 2026, total assets were $10.7 million against total liabilities of $45.4 million, leaving a shareholders’ deficit of $34.7 million. Cash and restricted cash totaled only $4.1 million, and current liabilities exceeded current assets by about $5.1 million, prompting explicit disclosure of substantial doubt about the company’s ability to continue as a going concern.
Aptose is heavily reliant on related-party financing from Hanmi. A loan payable to Hanmi and related facilities totaled $32.9 million plus $1.3 million of accrued interest, with additional advances received after quarter-end under a second amended facility of up to $11.1 million. In parallel, Aptose has agreed to a plan of arrangement under which a Hanmi subsidiary will acquire all remaining common shares for C$2.41 per share, canceling all incentive securities and warrants. Shareholders approved the transaction on March 31, 2026, and closing is expected in May 2026, subject to customary conditions and Korean regulatory approvals.
Aptose Biosciences Inc. filed its Q3 2025 report, highlighting ongoing development of tuspetinib while facing significant financial strain. The company reported a net loss of $5.1 million for the quarter and $17.7 million for the nine months. Cash, cash equivalents and restricted cash were $1.6 million as of September 30, 2025, with cash used in operations of $16.1 million year‑to‑date. Management states that conditions raise substantial doubt about the Company’s ability to continue as a going concern.
To fund operations, Aptose relied on related‑party facilities with Hanmi: an $8.5 million facility fully drawn and an additional up to $11.9 million facility, of which $4.2 million was advanced by October 27, 2025. Loan payable to related party rose to $18.7 million. Shareholders’ deficit widened to $(19.5) million. The company effected a 1‑for‑30 reverse stock split on February 26, 2025 and used an ATM to raise $1.0 million gross. 2,552,429 common shares were outstanding as of November 7, 2025.